Potential to become a new modality in the treatment of ulcerative colitis offering prolonged remission without immune suppressionThe study which compared MB310, a precision microbiome medicine, with ...

CAMBRIDGE - Microbiotica Ltd announced on Tuesday that its oral precision microbiome medicine MB310 demonstrated positive results in a Phase 1b trial for ulcerative colitis patients, meeting primary ...

Thetis Pharmaceuticals, LLC ("Thetis"), a clinical-stage company developing TP-317, a first-in-class, oral BLT1 agonist for inflammatory bowel disease (IBD) and cancer, today announced the appointment ...

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.

Flerie AB's (publ) portfolio company Microbiotica has reported positive results from its Phase 1b first-in-human study of MB310 in patients with ulcerative colitis (UC). The positive data support Micr ...

(Alliance News) - IP Group PLC on Wednesday said portfolio company Microbiotica Ltd has announced positive results from a phase 1b first-in-human trail of MB310 in ulcerative colitis patients.

MB310, a live biotherapeutic developed by Cambridge-based Microbiotica, achieves 63% remission rate in early study IP Group PLC (LSE:IPO), the London-listed investor in science and technology ...

The microbiome specialist, which for years has struggled to stay afloat, is cutting its staff by 30% and focusing resources on earlier, immunology-focused research.

Microscopic colitis (MC) is a chronic inflammatory bowel disease that severely reduces quality of life. MC is responsible for over 30% of all chronic diarrhea cases in people over 65 years of age, and ...

Researchers at Örebro University have identified blood markers that can indicate who is at risk of developing ulcerative ...

The chronic autoimmune conditions — both considered types of inflammatory bowel disease — cause a myriad of symptoms ...